<DOC>
	<DOCNO>NCT00692003</DOCNO>
	<brief_summary>Zonisamide already market treatment partial seizure epilepsy . This study intend provide evidence zonisamide safe effective treatment primary generalise tonic-clonic seizure . The total trial duration 5.5-6.5 month . After subject complete study eligible enrol open-label extension study zonisamide market indication development indication stop . This extension study describe separate protocol ( E2090-E044-316 ) .</brief_summary>
	<brief_title>Adjunctive Zonisamide Primary Generalised Tonic Clonic Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>1 . Subject male female age 665 year . 2 . Subject ≥ 3 PGTCS two month screen eight week Baseline Period least one seizure one month period . PGTCS must occur context Idiopathic Generalized Epilepsy ( IGE ) may accompany primary generalized seizure , provide also consistent diagnosis IGE . 3 . Subject ( parent/caregiver , subject age consent ) willing sign inform consent form . For subject age consent country , appropriate must willing give inform ( write verbal ) assent . Subjects age specify local regulation require sign appropriate inform consent form . 4 . Subject take stable regimen one two Antiepileptic Drugs ( AEDs ) least two week prior Visit 1 ( start Baseline Period ) . 5 . Subject clinical diagnosis type idiopathic generalize epilepsy PGTCS ( may accompany generalized seizure type ) , accord International League Against Epilepsy ( ILAE ) Classification Epileptic Seizures ( 1981 ) ILAE Classification Epilepsies Epileptic Syndromes ( 1989 ) . Diagnosis establish clinical history , electroencephalogram ( EEG ) compute tomography/magnetic resonance imaging ( CT/MRI ) brain consistent idiopathic generalize epilepsy . CT/MRI scan perform within five year screen visit , available period , performed Baseline Period . 6 . EEG perform within one year screen visit , available period , performed Baseline Period . 7 . Female subject premenarchal , childbearing potential , pregnant lactating postmenopausal . 8 . Female subject childbearing potential must abide one follow medically acceptable contraceptive measure : oral contraception pill , contraceptive injection , implant patch , intrauterine device place least three month vasectomise partner abstinence throughout study . 9 . Subject body weight ≥ 20 kg . 1 . Subject progressive focal neurological disease ( determined preexist brain image CT MRI perform maximally five year screen visit ) , clinically significant organic disease . 2 . Subject history , result clinical investigation ( include EEG data ) suggestive , partial seizure define ILAE , include generalize tonic clonic seizure suspect secondarily generalize . 3 . Subjects cryptogenic symptomatic generalize epilepsy . 4 . Subjects psychogenic seizure . 5 . Subject history status epilepticus within year screen comply AEDs . 6 . Subject seizure occur cluster pattern . 7 . Subject history renal calculus renal insufficiency ( upper normal limit creatinine ) . 8 . Subject know diagnosis human immunodeficiency virus ( HIV ) hepatitis B C. 9 . Subject predispose condition might interfere absorption , distribution , excretion zonisamide . 10 . Subject history sensitivity sulfonamide drug zonisamide excipients . 11 . Subject recent history excessive alcohol use drug abuse . 12 . Subject history suicide attempt five year screen visit.. 13 . Subject abnormal screen laboratory value clinically significant . 14 . Subject history demonstrate noncompliance treatment subject parent/caregiver reasonably expect compliant study procedure complete study . 15 . Subject participate study investigational drug device within 30 day prior screen . 16 . Subject receive previous treatment zonisamide . 17 . Subject treat ketogenic diet vagus nerve stimulator . 18 . Subject history necessary treatment rescue benzodiazepine foreseen continue study . Rescue benzodiazepine allow study ( stable dose benzodiazepine ( one ) baseline antiepileptic drug ( ) allow ) . 19 . Current psychosis moderate severe depression , use antipsychotic drug , MAOIs , tricyclic antidepressant , benzodiazepine barbiturate treatment disorder epilepsy , stimulant ( amphetamine derivative ) within 28 day screen visit . 20 . Concomitant use acetazolamide , carbonic anhydrase inhibitor topiramate drug anticholinergic activity . 21 . Concomitant use felbamate use felbamate within two month prior Visit 1 . 22 . Subject able swallow capsule . 23 . Subject general good health determine medical history , physical exam screen laboratory result .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>